Anti-topoisomerase (Scl-70) antibodies are highly specific for SSc and have been associated with diffuse skin involvement and interstitial lung fibrosis. Patients with SSc and anti-topoisomerase (Scl-70) antibodies, may be at greater risk of developing ILD and disease progression. In contrast, patients with SSc and anti-centromere antibodies rarely develop SSc-ILD.
Learn more about CTD-ILD.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Scleroderma Systemic Sclerosis ILD Presentation and Diagnosis - Medscape - Mar 28, 2023.